Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.93 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.93 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.93 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.93 |
| ▸ | LMNA | P02545 | 6/20 | 0.60 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.60 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.60 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KDM5C | P41229 | 3/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.41 |
| ▸ | KDM6B | O15054 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alpha-Ketoglutaric Acid SCHEMBL30208560 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL7400 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL29783374 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL17127347 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL932116 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL3776640 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL30029036 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL3184813 | 0.93 | EGLN1 (0.93) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL1428274 | 0.93 | EGLN1 (0.93) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL20594156 | 0.93 | EGLN1 (0.93) | EGLN1OR51E2MAPK1SLC13A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100062087-A1 | Nutraceutical Treatments for Diabetic and Non-Diabetic Wound Healing | INTERHEALTH NUTRACEUTICALS, INC. (CA) | 2010-03-11 | — | — | US | claimed |
| US-20080003303-A1 | Nutraceutical treatments for diabetic and non-diabetic wound healing | INTERHEALTH NUTRACEUTICALS INC. (US) | 2008-01-03 | — | — | US | claimed |
| WO-2007143631-A2 | NUTRACEUTICAL TREATMENTS FOR DIABETIC AND NON-DIABETIC WOUND HEALING | INTERHEALTH NUTRACEUTICALS, INC. (US) | 2007-12-13 | — | — | WO | claimed |
| JP-11302184-A | — | — | None | — | — | JP | disclosed |
| CN-112955139-B | Process for preparing alpha-ketoglutarate calcium | 庞塞迪利昂健康特定活动公司 | 2025-04-18 | — | — | CN | disclosed |
| US-11802103-B2 | Process of making calcium alpha-ketoglutarate | PONCE DE LEON HEALTH DESIGNATED ACTIVITY COMPANY (IE) | 2023-10-31 | — | — | US | disclosed |
| US-20210371368-A1 | PROCESS OF MAKING CALCIUM ALPHA-KETOGLUTARATE | PEREIRA DAVID EUGENE (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3856166-A1 | PROCESS OF MAKING CALCIUM ALPHA-KETOGLUTARATE | Ponce de Leon Health Designated Activity Company (IE) | 2021-08-04 | — | — | EP | disclosed |
| CN-112955139-A | Process for the preparation of calcium alpha-ketoglutarate | 庞塞迪利昂健康特定活动公司 | 2021-06-11 | — | — | CN | disclosed |
| WO-2020068705-A1 | PROCESS OF MAKING CALCIUM ALPHA-KETOGLUTARATE | PONCE DE LEON HEALTH DESIGNATED ACTIVITY COMPANY (IE) | 2020-04-02 | — | — | WO | disclosed |
| CN-109689035-A | Composition comprising choline | 巴尔化学公司 | 2019-04-26 | — | — | CN | disclosed |
| US-20060292094-A1 | Composition and method of protection against UV irradiation | PURE LABORATORIES, LLC | 2006-12-28 | — | — | US | disclosed |
| US-20030108624-A1 | Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus | KOSBAB JOHN V (US) | 2003-06-12 | — | — | US | disclosed |
| EP-1021177-A4 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES | KOSBAB JOHN V (US) | 2002-05-15 | — | — | EP | disclosed |
| US-20010031744-A1 | Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus | KOSBAB JOHN V (US) | 2001-10-18 | — | — | US | disclosed |
| EP-1100517-A1 | NUTRIENT AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF CANCER | Kosbab, John V. (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1021177-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES | Kosbab, John V. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000007607-A1 | NUTRIENT AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF CANCER | KOSBAB, JOHN, V. (US) | 2000-02-17 | — | — | WO | disclosed |
| JP-H11302184-A | NASAL COMPOSITION | TAISHO PHARMACEUT CO LTD | 1999-11-02 | — | — | JP | disclosed |
| WO-1998033494-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES | KOSBAB JOHN V (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371368-A1 | PROCESS OF MAKING CALCIUM ALPHA-KETOGLUTARATE | HOGA1, OGDH, GLS | EGLN1 211/4885OR51E2 4773/4885MAPK1 3925/4885 |
| US-11802103-B2 | Process of making calcium alpha-ketoglutarate | HOGA1, OGDH, GLS | EGLN1 211/4885OR51E2 4773/4885MAPK1 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.